- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
CTCs and LDH: Surrogates for Survival in Advanced Prostate Cancer
The trial, whose results were published in the Journal of Clinical Oncology, found that circulating tumor cells and lactose dehydrogenase are ideal surrogates to predict overall survival in patients with advanced prostate cancer.
A biomarker panel of circulating tumor cell count plus lactate dehydrogenase level met criteria as a surrogate for overall survival in individual patients with castration-resistant prostate cancer, according to research published online March 23 in the Journal of Clinical Oncology.
Recent progress in prostate cancer therapy has created the need for reliable post-treatment outcome measures that are surrogates for survival to guide patient management and to aid in the regulatory approval process. Investigators sought to identify an efficacy-response surrogate, to be confirmed in future trials, within the phase III clinical trial for abiraterone acetate plus prednisone vs. prednisone alone for patients with castration-resistant prostate cancer.
“Such a surrogate would shorten drug development times and eliminate the potential confounding effects of post protocol therapy on survival,” wrote Dr Howard I. Scher, head of the genitourinary oncology service at the Sidney Kimmel Center for Urologic and Prostate Cancers at Memorial Sloan Kettering Cancer Center, New York, and associates.
Link to the report on Oncology Practice:
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
